The IGF Pathway Regulates ERα through a S6K1-Dependent Mechanism in Breast Cancer Cells
Authors:
Open Access
- 1 March 2011
- journal article
- research article
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 25 (3) , 516-528
Abstract
The IGF pathway stimulates malignant behavior of breast cancer cells. Herein we identify the mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) axis as a critical component of IGF and estrogen receptor (ER)α cross talk. The insulin receptor substrate (IRS) adaptor molecules function downstream of IGF-I receptor and dictate a specific biological response, in which IRS-1 drives proliferation and IRS-2 is linked to motility. Although rapamycin-induced mTOR inhibition has been shown to block IGF-induced IRS degradation, we reveal differential effects on motility (up-regulation) and proliferation (down-regulation). Because a positive correlation between IRS-1 and ERα expression is thought to play a central role in the IGF growth response, we investigated the potential role of ERα as a downstream mTOR target. Small molecule inhibition and targeted knockdown of S6K1 blocked the IGF-induced ERαS167 phosphorylation and did not influence ligand-dependent ERαS118 phosphorylation. Inhibition of S6K1 kinase activity consequently ablated IGF-stimulated S6K1/ERα association, estrogen response element promoter binding and ERα target gene transcription. Moreover, site-specific ERαS167 mutation reduced ERα target gene transcription and blocked IGF-induced colony formation. These findings support a novel link between the IGF pathway and ERα, in which the translation factor S6K1 affects transcription of ERα-regulated genes.Keywords
This publication has 83 references indexed in Scilit:
- Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulationOncogene, 2010
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- AKT Alters Genome-Wide Estrogen Receptor α Binding and Impacts Estrogen Signaling in Breast CancerMolecular and Cellular Biology, 2008
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceEndocrine Reviews, 2008
- Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cellsBritish Journal of Cancer, 2006
- Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target PromoterCell, 2003
- Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated TranscriptionCell, 2000
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000
- Mutant IGF-I Receptors as Dominant Negatives for Growth and TransformationBiochemical and Biophysical Research Communications, 1995
- Estrogen Receptors and Responses to Chemotherapy and Hormonal Therapy in Advanced Breast CancerNew England Journal of Medicine, 1978